Katherine L Nathanson


Affiliation: University of Pennsylvania
Country: USA


  1. Nathanson K, Domchek S. Therapeutic approaches for women predisposed to breast cancer. Annu Rev Med. 2011;62:295-306 pubmed publisher
    ..PARP inhibitors represent a novel therapeutic strategy that exploits the weaknesses of BRCA1/2-associated malignancies. ..
  2. Haas N, Nathanson K. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 2014;21:81-90 pubmed publisher
    ..The targeted therapeutic options for the kidney cancer associated with these diseases are just starting to expand and are an area of active clinical research. ..
  3. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015;17:61 pubmed publisher
    ..This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects. ..
  4. Wilson M, Zhao F, Khare S, Roszik J, Woodman S, D Andrea K, et al. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016;22:374-82 pubmed publisher
    ..These genomic alterations should be incorporated in future studies for evaluation as biomarkers. ..
  5. Yang R, Mick R, Lee K, Graves H, Nathanson K, Domchek S, et al. DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. J Transl Med. 2015;13:335 pubmed publisher
    ..Oncodrivers HER3 and C-MET were expressed in the DCIS of mutation carriers, suggesting an opportunity for prevention strategies. ..
  6. Sargen M, Merrill S, Chu E, Nathanson K. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. Br J Dermatol. 2016;175:785-9 pubmed publisher
    ..We also present a discussion of medical management for patients with this high-risk cancer susceptibility syndrome. ..
  7. Pyle L, Nathanson K. Genetic changes associated with testicular cancer susceptibility. Semin Oncol. 2016;43:575-581 pubmed publisher
  8. Silvestri V, Barrowdale D, Mulligan A, Neuhausen S, Fox S, Karlan B, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18:15 pubmed publisher
    ..e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management. ..
  9. Nathanson K, Martin A, Wubbenhorst B, Greshock J, Letrero R, D Andrea K, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013;19:4868-78 pubmed publisher
    ..The results suggest that these markers should be considered in the design and interpretation of future trials with selective BRAF inhibitors in advanced melanoma patients. ..

More Information


  1. Maxwell K, Hart S, Vijai J, Schrader K, Slavin T, Thomas T, et al. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. Am J Hum Genet. 2016;98:801-817 pubmed publisher
    ..Additionally, evaluation of extended panels of cancer-associated genes in breast/ovarian cancer families leads to only an incremental clinical benefit but substantially increases the complexity of the results. ..
  2. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson A, Johnson A, et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017;31:181-193 pubmed publisher
    ..Correlates of metastatic PCCs/PGLs included the MAML3 fusion gene. This integrated molecular characterization provides a comprehensive foundation for developing PCC/PGL precision medicine. ..
  3. Maxwell K, Wubbenhorst B, Wenz B, De Sloover D, Pluta J, Emery L, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8:319 pubmed publisher
    ..Herein, the authors identify that a subset of breast/ovarian tumors retain a normal allele, which is associated with decreased overall survival after DNA damage-inducing platinum chemotherapy. ..